{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:41:32Z","timestamp":1788176492908,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T00:00:00Z","timestamp":1563235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00059-019-4823-6","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T12:12:54Z","timestamp":1563279174000},"page":"491-501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Pulmonary hypertension and valvular heart disease","Pulmonale Hypertonie und Herzklappenerkrankungen"],"prefix":"10.1007","volume":"44","author":[{"given":"T.","family":"Tichelb\u00e4cker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gerhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wissm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Frerker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Halbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Baldus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rosenkranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"key":"4823_CR1","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-2600(15)00543-3","volume":"4","author":"MM Hoeper","year":"2016","unstructured":"Hoeper MM, Humbert M, Souza R et\u00a0al (2016) A global view of pulmonary hypertension. Lancet Respir Med 4:306\u2013322","journal-title":"Lancet Respir Med"},{"key":"4823_CR2","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","volume":"53","author":"G Simonneau","year":"2019","unstructured":"Simonneau G, Montani D, Celermajer DS et\u00a0al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir\u00a0J 53:1801913","journal-title":"Eur Respir J"},{"key":"4823_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","volume":"37","author":"S Rosenkranz","year":"2016","unstructured":"Rosenkranz S, Gibbs JSR, Wachter R et\u00a0al (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart\u00a0J 37:942\u2013954","journal-title":"Eur Heart J"},{"key":"4823_CR4","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/j.amjcard.2013.07.025","volume":"112","author":"DM Zlotnick","year":"2013","unstructured":"Zlotnick DM, Ouellette ML, Malenka DJ et\u00a0al (2013) Effect of pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. Am J Cardiol 112:1635\u20131640","journal-title":"Am J Cardiol"},{"key":"4823_CR5","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.jtcvs.2011.02.028","volume":"141","author":"SJ Melby","year":"2011","unstructured":"Melby SJ, Moon MR, Lindman BR et\u00a0al (2011) Impact of pulmonary hypertension on outcomes after aortic valve replacement for aortic valve stenosis. J\u00a0Thorac Cardiovasc Surg 141:1424\u20131430","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4823_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jtcvs.2016.02.038","volume":"152","author":"B Yang","year":"2016","unstructured":"Yang B, De Benedictus C, Watt T et\u00a0al (2016) The impact of concomitant pulmonary hypertension on early and late outcomes following surgery for mitral stenosis. J\u00a0Thorac Cardiovasc Surg 152:394\u2013400","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4823_CR7","doi-asserted-by":"crossref","first-page":"e002358","DOI":"10.1161\/CIRCINTERVENTIONS.114.002358","volume":"8","author":"CJ O\u2019Sullivan","year":"2015","unstructured":"O\u2019Sullivan CJ, Wenaweser P, Ceylan O et\u00a0al (2015) Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 8:e2358","journal-title":"Circ Cardiovasc Interv"},{"key":"4823_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCINTERVENTIONS.113.000482","volume":"7","author":"A Lu\u00e7on","year":"2014","unstructured":"Lu\u00e7on A, Oger E, Bedossa M et\u00a0al (2014) Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the FRANCE 2 registry. Circ Cardiovasc Interv 7:240\u2013247","journal-title":"Circ Cardiovasc Interv"},{"key":"4823_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.4244\/EIJV9I9A177","volume":"9","author":"JM Sinning","year":"2014","unstructured":"Sinning JM, Hammerstingl C, Chin D et\u00a0al (2014) Decrease of pulmonary hypertension impacts on prognosis after transcatheter aortic valve replacement. EuroIntervention 9:1042\u20131049","journal-title":"EuroIntervention"},{"key":"4823_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1136\/heartjnl-2017-311978","volume":"104","author":"A Masri","year":"2018","unstructured":"Masri A, Abdelkarim I, Sharbaugh MS et\u00a0al (2018) Outcomes of persistent pulmonary hypertension following transcatheter aortic valve replacement. Heart 104:821\u2013827","journal-title":"Heart"},{"key":"4823_CR11","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/ejhf.864","volume":"20","author":"E Tigges","year":"2018","unstructured":"Tigges E, Blankenberg S, von Bardeleben RS et\u00a0al (2018) Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 20:585\u2013594","journal-title":"Eur J Heart Fail"},{"key":"4823_CR12","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.jacc.2016.03.589","volume":"67","author":"A Mentias","year":"2016","unstructured":"Mentias A, Patel H, Patel K et al (2016) Effect of pulmonary vascular pressures on long-term outcome in patients with primary mitral regurgitation. J\u00a0Am Coll Cardiol 67:2952\u20132961","journal-title":"J Am Coll Cardiol"},{"key":"4823_CR13","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/echo.14125","volume":"35","author":"F Gual-Capllonch","year":"2018","unstructured":"Gual-Capllonch F, Teis A, Ferrer E et al (2018) Pulmonary vascular resistance versus pulmonary artery pressure for predicting right ventricular remodeling and functional tricuspid regurgitation. Echocardiography 35:1736\u20131745","journal-title":"Echocardiography"},{"key":"4823_CR14","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.4244\/EIJ-D-17-00704","volume":"13","author":"M Taramasso","year":"2018","unstructured":"Taramasso M, Pazzoli A, Basso C et\u00a0al (2018) Compare and contrast tricuspid and mitral valve anatomy: interventional perspectives for transcatheter tricuspid valve therapies. EuroIntervention 13:1889\u20131898","journal-title":"EuroIntervention"},{"key":"4823_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL et\u00a0al (2016) 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart\u00a0J 37:67\u2013119","journal-title":"Eur Heart J"},{"key":"4823_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCULATIONAHA.115.020207","volume":"133","author":"BA Maron","year":"2016","unstructured":"Maron BA, Hess E, Maddox TM et\u00a0al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a\u00a0large patient cohort: Insights from the Veterans Affairs clinical assessment, reporting, and tracking program. Circulation 133:1240\u20131248","journal-title":"Circulation"},{"key":"4823_CR17","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1001\/jamacardio.2017.3882","volume":"2","author":"TR Assad","year":"2017","unstructured":"Assad TR, Maron BA, Robbins IM et\u00a0al (2017) Prognostic effect and longitudinal hemodynamic assessment of borderline pulmonary hypertension. JAMA Cardiol 2:1361\u20131368","journal-title":"JAMA Cardiol."},{"key":"4823_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1164\/rccm.201706-1215OC","volume":"197","author":"P Douschan","year":"2018","unstructured":"Douschan P, Kovacs G, Avian A et\u00a0al (2018) Mild elevation of pulmonary arterial pressure as a\u00a0predictor of mortality. Am J Respir Crit Care Med 197:509\u2013516","journal-title":"Am J Respir Crit Care Med"},{"key":"4823_CR19","doi-asserted-by":"publisher","first-page":"e009729","DOI":"10.1161\/JAHA.118.009729","volume":"7","author":"D Kolte","year":"2018","unstructured":"Kolte D, Lakshmanan S, Jankowich MD et al (2018) Mild pulmonary hypertension is associated with increased mortality: a systematic review and meta-analysis. J\u00a0Am Heart Assoc 7:e9729","journal-title":"J Am Heart Assoc"},{"key":"4823_CR20","doi-asserted-by":"crossref","unstructured":"Vachi\u00e9ry JL, Tedford RJ, Rosenkranz S et\u00a0al (2019) Pulmonary hypertension due to left heart disease. Eur Respir\u00a0J. https:\/\/doi.org\/10.1183\/13993003.01897\u20132018","DOI":"10.1183\/13993003.01897-2018"},{"key":"4823_CR21","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.ijcard.2018.08.080","volume":"272","author":"S Rosenkranz","year":"2018","unstructured":"Rosenkranz S, Lang IM, Blind R et\u00a0al (2018) Pulmonary hypertension associated with left heart disease: updated recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 272:S53\u2013S62","journal-title":"Int J Cardiol"},{"key":"4823_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","volume":"3","author":"RR Vanderpool","year":"2018","unstructured":"Vanderpool RR, Saul M, Nouraie M et\u00a0al (2018) Association between hemodynamic markers of pulmonary hypertension and outcomes in patients with heart failure and preserved ejection fraction. JAMA Cardiol 3:298\u2013306","journal-title":"JAMA Cardiol."},{"key":"4823_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ejhf.860","volume":"20","author":"M Palazzini","year":"2018","unstructured":"Palazzini M, Dardi F, Manes A et al (2018) Pulmonary hypertension due to left-heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC\/ERS guidelines and new insights for future changes. Eur J Heart Fail 20:248\u2013255","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"4823_CR24","doi-asserted-by":"publisher","first-page":"1702427","DOI":"10.1183\/13993003.02427-2017","volume":"51","author":"S Caravita","year":"2018","unstructured":"Caravita S, Dewachter C, Soranna D et al (2018) Haemodynamics to predict outcome in pulmonary hypertension due to left heart disease: a\u00a0meta-analysis. Eur Respir\u00a0J 51(4):1702427","journal-title":"Eur Respir J"},{"key":"4823_CR25","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jacc.2017.01.051","volume":"69","author":"M Guazzi","year":"2017","unstructured":"Guazzi M, Naeije R (2017) Pulmonary hypertension in heart failure: Pathophysiology, pathobiology, and emerging\u00a0clinical\u00a0perspectives. J\u00a0Am Coll Cardiol 69:1718\u20131734","journal-title":"J Am Coll Cardiol"},{"key":"4823_CR26","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/S0140-6736(09)60994-6","volume":"374","author":"Y Chandrashekhar","year":"2009","unstructured":"Chandrashekhar Y, Westaby S, Narula J (2009) Mitral stenosis. Lancet 374:1271\u20131283","journal-title":"Lancet"},{"key":"4823_CR27","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1136\/hrt.19.2.279","volume":"19","author":"P Wood","year":"1957","unstructured":"Wood P, Besterman EM, Towers MK, Mcilroy MB (1957) The effect of acetylcholine on pulmonary vascular resistance and left atrial pressure in mitral stenosis. Br Heart\u00a0J 19:279\u2013286","journal-title":"Br Heart J"},{"key":"4823_CR28","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJM196509022731001","volume":"273","author":"E Braunwald","year":"1965","unstructured":"Braunwald E, Braunwald NS, Ross J, Morrow AG (1965) Effects of mitral valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension. N\u00a0Engl J Med 273:509\u2013514","journal-title":"N Engl J Med"},{"key":"4823_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJM196708242770801","volume":"277","author":"JE Dalen","year":"1967","unstructured":"Dalen JE, Matloff JM, Evans GL et al (1967) Early reduction of pulmonary vascular resistance after mitral-valve replacement. N\u00a0Engl J Med 277:387\u2013394","journal-title":"N Engl J Med"},{"key":"4823_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/0002-9149(91)90060-X","volume":"67","author":"V Dev","year":"1991","unstructured":"Dev V, Shrivastava S (1991) Time course of changes in pulmonary vascular resistance and the mechanism of regression of pulmonary arterial hypertension after balloon mitral valvuloplasty. Am J Cardiol 67:439\u2013442","journal-title":"Am J Cardiol"},{"key":"4823_CR31","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.jtcvs.2015.07.012","volume":"150","author":"M Tsukashita","year":"2015","unstructured":"Tsukashita M, Takayama H, Takeda K et al (2015) Effect of pulmonary vascular resistance before left ventricular assist device implantation on short- and long-term post-transplant survival. J\u00a0Thorac Cardiovasc Surg 150:1352\u20131361","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4823_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.cardfail.2016.06.421","volume":"23","author":"SG Al Kindi","year":"2017","unstructured":"Al Kindi SG, Farhoud M et\u00a0al (2017) Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation. J\u00a0Card Fail 23:209\u2013215","journal-title":"J Card Fail."},{"key":"4823_CR33","doi-asserted-by":"publisher","first-page":"e003882","DOI":"10.1161\/CIRCHEARTFAILURE.117.003882","volume":"10","author":"F Imamura","year":"2017","unstructured":"Imamura F, Chung B, Nguyen A et\u00a0al (2017) Decoupling between diastolic pulmonary artery pressure and pulmonary capillary wedge pressure as a\u00a0prognostic factor after continuous flow ventricular assist device implantation. Circ Heart Fail 10:e3882","journal-title":"Circ Heart Fail"},{"key":"4823_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/eurjhf\/hfq014","volume":"12","author":"F Bursi","year":"2010","unstructured":"Bursi F, Barbieri A, Grigioni F et al (2010) Prognostic implications of functional mitral regurgitation according to the severity of the underlying chronic heart failure: a\u00a0long-term outcome study. Eur J Heart Fail 12:382\u2013388","journal-title":"Eur J Heart Fail"},{"key":"4823_CR35","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.amjcard.2015.02.028","volume":"115","author":"P Lancellotti","year":"2015","unstructured":"Lancellotti P, Magne J, Dulgheru R et\u00a0al (2015) Clinical significance of exercise pulmonary hypertension in secondary mitral regurgitation. Am J Cardiol 115:1454\u20131461","journal-title":"Am J Cardiol"},{"key":"4823_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1161\/CIRCIMAGING.112.000162","volume":"6","author":"K Kusunose","year":"2013","unstructured":"Kusunose K, Popovi\u0107 ZB, Motoki H, Marwick TH (2013) Prognostic significance of exercise-induced right ventricular dysfunction in asymptomatic degenerative mitral regurgitation. Circ Cardiovasc Imaging 6:167\u2013176","journal-title":"Circ Cardiovasc Imaging"},{"key":"4823_CR37","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/heartjnl-2011-300705","volume":"98","author":"O Gaemperli","year":"2012","unstructured":"Gaemperli O, Moccetti M, Surder D et al (2012) Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 98:126\u2013132","journal-title":"Heart"},{"key":"4823_CR38","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone GW, Lindenfeld J, Abraham WT et al (2018) Transcatheter mitral-valve repair in patients with heart failure. N\u00a0Engl J Med 379:2307\u20132318","journal-title":"N Engl J Med"},{"key":"4823_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0002-9149(99)00643-8","volume":"85","author":"P Faggiano","year":"2000","unstructured":"Faggiano P, Antonini-Canterin F, Ribichini F et al (2000) Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 85:204\u2013208","journal-title":"Am J Cardiol"},{"key":"4823_CR40","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00392-011-0367-3","volume":"101","author":"CS Zuern","year":"2012","unstructured":"Zuern CS, Eick C, Rizas K et al (2012) Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement. Clin Res Cardiol 101:81\u201388","journal-title":"Clin Res Cardiol"},{"key":"4823_CR41","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1010-7940(99)00106-2","volume":"15","author":"F Roques","year":"1999","unstructured":"Roques F, Nashef SA, Michel P et\u00a0al (1999) Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 15:816\u2013822","journal-title":"Eur J Cardiothorac Surg"},{"key":"4823_CR42","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","volume":"364","author":"CR Smith","year":"2011","unstructured":"Smith CR, Leon MB, Mack MJ et al (2011) Transcatheter versus surgical aortic-valve replacement in high-risk patients. N\u00a0Engl J Med 364:2187\u20132198","journal-title":"N Engl J Med"},{"key":"4823_CR43","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1700456","volume":"376","author":"MJ Reardon","year":"2017","unstructured":"Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N\u00a0Engl J Med 376:1321\u20131331","journal-title":"N Engl J Med"},{"key":"4823_CR44","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","volume":"374","author":"MB Leon","year":"2016","unstructured":"Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N\u00a0Engl J Med 374:1609\u20131620","journal-title":"N Engl J Med"},{"key":"4823_CR45","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa1816885","volume":"380","author":"MJ Mack","year":"2019","unstructured":"Mack MJ, Leon MB, Thourani VH et al (2019) Transcatheter aortic-valve replacement with a\u00a0balloon-expandable valve in low-risk patients. N\u00a0Engl J Med 380:1706\u20131715","journal-title":"N Engl J Med"},{"key":"4823_CR46","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1164\/rccm.200811-1691OC","volume":"179","author":"MR Fisher","year":"2009","unstructured":"Fisher MR, Forfia PR, Chamera E et\u00a0al (2009) Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 179:615\u2013621","journal-title":"Am J Respir Crit Care Med"},{"key":"4823_CR47","doi-asserted-by":"publisher","first-page":"e012240","DOI":"10.1136\/bmjopen-2016-012240","volume":"7","author":"A Marciniak","year":"2017","unstructured":"Marciniak A, Klover K, Sharma R (2017) Cohort profile: prevalence of valvular heart disease in community patients with suspected heart failure in UK. BMJ Open 7:e12240","journal-title":"BMJ Open"},{"key":"4823_CR48","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/eurheartj\/ehy641","volume":"40","author":"N Wang","year":"2019","unstructured":"Wang N, Fulcher J, Abeysuriya N et al (2019) Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a\u00a0systematic review and meta-analysis. Eur Heart\u00a0J 40:476\u2013484","journal-title":"Eur Heart J"},{"key":"4823_CR49","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jcmg.2018.06.014","volume":"12","author":"Y Topilsky","year":"2019","unstructured":"Topilsky Y, Maltais S, Medina Inojosa J et\u00a0al (2019) Burden of tricuspid regurgitation in\u00a0patients diagnosed in the community\u00a0setting. JACC Cardiovasc Imaging 12:433\u2013442","journal-title":"JACC Cardiovasc Imaging"},{"key":"4823_CR50","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jcmg.2014.07.018","volume":"7","author":"Y Topilsky","year":"2014","unstructured":"Topilsky Y, Nkomo VT, Vatury O et\u00a0al (2014) Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging 7:1185\u20131194","journal-title":"JACC Cardiovasc. Imaging"},{"key":"4823_CR51","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1161\/CIRCULATIONAHA.116.024848","volume":"135","author":"G Nickenig","year":"2017","unstructured":"Nickenig G, Kowalsi M, Hausleiter J et al (2017) Transcatheter treatment of severe tricuspid regurgitation with the edge-to-edge MitraClip technique. Circulation 135:1802\u20131814","journal-title":"Circulation"},{"key":"4823_CR52","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1093\/eurheartj\/ehy352","volume":"39","author":"EA Prihadi","year":"2018","unstructured":"Prihadi EA, van der Bijl P, Gursoy E et\u00a0al (2018) Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history. Eur Heart\u00a0J 39:3574\u20133581","journal-title":"Eur Heart J"},{"key":"4823_CR53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jcmg.2018.09.027","volume":"12","author":"EA Prihadi","year":"2019","unstructured":"Prihadi EA, Delgado V, Leon MB et\u00a0al (2019) Morphologic types of tricuspid\u00a0regurgitation: characteristics and prognostic implications. JACC Cardiovasc Imaging 12:491\u2013499","journal-title":"JACC Cardiovasc. Imaging"},{"key":"4823_CR54","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1183\/09031936.00049312","volume":"41","author":"IM Lang","year":"2013","unstructured":"Lang IM, Pesavento R, Bonderman D, Yuan JX (2013) Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a\u00a0current understanding. Eur Respir\u00a0J 41:462\u2013468","journal-title":"Eur Respir J"},{"key":"4823_CR55","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.jacc.2018.04.009","volume":"71","author":"E Mahmud","year":"2018","unstructured":"Mahmud E, Madani MM, Kim NH et\u00a0al (2018) Chronic thromboembolic pulmonary\u00a0hypertension: evolving therapeutic approaches for operable and inoperable\u00a0disease. J\u00a0Am Coll Cardiol 71:2468\u20132486","journal-title":"J Am Coll Cardiol"},{"key":"4823_CR56","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/ehjci\/jew010","volume":"18","author":"D Medvedofsky","year":"2017","unstructured":"Medvedofsky D, Aronson D, Gomberg-Maitland M et al (2017) Tricuspid regurgitation progression and regression in pulmonary arterial hypertension: implications for right ventricular and tricuspid valve apparatus geometry and patients outcome. Eur Heart J Cardiovasc Imaging 18:86\u201394","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"4823_CR57","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/heartjnl-2014-306801","volume":"101","author":"P De Meester","year":"2015","unstructured":"De Meester P, De Cock D, Van De Bruaene A et\u00a0al (2015) Additional tricuspid annuloplasty in mitral valve surgery results in better clinical outcome. Heart 101:720\u2013726","journal-title":"Heart"},{"key":"4823_CR58","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2015.01.059","volume":"65","author":"J Chickwe","year":"2015","unstructured":"Chickwe J, Itagaki S, Anyanwu A, Adams DH (2015) Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J\u00a0Am Coll Cardiol 65:1931\u20131938","journal-title":"J Am Coll Cardiol"},{"key":"4823_CR59","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1093\/eurheartj\/ehw241","volume":"37","author":"B Borlaug","year":"2016","unstructured":"Borlaug B, Kane GC, Melenovsky V, Olson TP (2016) Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart\u00a0J 37:3293\u20133302","journal-title":"Eur Heart J"},{"key":"4823_CR60","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","volume":"139","author":"DH Kang","year":"2019","unstructured":"Kang DH, Park SJ, Shin SH et\u00a0al (2019) Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation 139:1354\u20131365","journal-title":"Circulation"},{"key":"4823_CR61","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","volume":"39","author":"J Bermejo","year":"2018","unstructured":"Bermejo J, Yotti R, Garc\u00eda-Orta R et al (2018) Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a\u00a0multicenter, double-blind, randomized clinical trial. Eur Heart\u00a0J 39:1255\u20131264","journal-title":"Eur Heart J"},{"key":"4823_CR62","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ et\u00a0al (2017) 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart\u00a0J 38:2739\u20132791","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4823-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-019-4823-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-019-4823-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T23:58:37Z","timestamp":1663977517000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-019-4823-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4823"],"URL":"https:\/\/doi.org\/10.1007\/s00059-019-4823-6","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,16]]},"assertion":[{"value":"16 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"T.\u00a0Tichelb\u00e4cker, M.\u00a0Wissm\u00fcller, C.\u00a0Frerker, M.\u00a0Halbach, and S.\u00a0Baldus declare that they have no competing interests. D.\u00a0Dumitrescu declares honoraria for lectures and\/or consultancy from Actelion, Bayer, GSK, Novartis, Pfizer, Servier; participation in clinical trials for Actelion, Bayer, GSK, Novartis; and research support to institution from Actelion. F.\u00a0Gerhardt declares remunerations for lectures and\/or consultancy from Actelion, Bayer, GSK, MSD, and United Therapeutics; grants to institution from Actelion, Bayer, Novartis, und United Therapeutics. D.\u00a0Stern declares honoraria for lectures from Actelion. M.\u00a0Adam declares remunerations for lectures and\/or consultancy from Edwards LifeSciences. T.\u00a0Schmidt declares remunerations for lectures and\/or consultancy from Edwards LifeSciences. R.\u00a0Pfister declares speaker fees and travel support from Abbott Vascular, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Edwards LifeSciences, Novartis, Orion Pharma, Pfizer, and Servier. S.\u00a0Rosenkranz declares remunerations for lectures and\/or consultancy from Abbott, Actelion, Arena, Bayer, Ferrer, GSK, MSD, Novartis, Pfizer, and United Therapeutics; research support to institution from Actelion, Bayer, Novartis, Pfizer, and United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}